UTILITY VALUES FOR HEALTH STATES ASSOCIATED WITH DUCHENNE MUSCULAR DYSTROPHY: A SYSTEMATIC REVIEW

被引:0
作者
Szabo, S. [1 ]
Audhya, I. F. [2 ]
Malone, D. C. [3 ]
Feeny, D. [4 ]
Gooch, K. [2 ]
机构
[1] Broadst Hlth Econ & Outcomes Res, Vancouver, BC, Canada
[2] Sarepta Therapeut, Cambridge, MA USA
[3] Univ Arizona, Tucson, AZ USA
[4] McMaster Univ, Hamilton, ON, Canada
关键词
D O I
暂无
中图分类号
F [经济];
学科分类号
02 ;
摘要
PRO67
引用
收藏
页码:S853 / S853
页数:1
相关论文
共 50 条
[21]   The impact of genotype on outcomes in individuals with Duchenne muscular dystrophy: A systematic review [J].
Szabo, Shelagh M. ;
Gooch, Katherine L. ;
Mickle, Alexis T. ;
Salhany, Renna M. ;
Connolly, Anne M. .
MUSCLE & NERVE, 2022, 65 (03) :266-277
[22]   Understanding carer resilience in Duchenne muscular dystrophy: A systematic narrative review [J].
Glover, Suzanne ;
Hendron, Jill ;
Taylor, Brian ;
Long, Maggie .
CHRONIC ILLNESS, 2020, 16 (02) :87-103
[23]   Restorative treatments of dystrophin expression in Duchenne muscular dystrophy: A systematic review [J].
Pascual-Morena, Carlos ;
Cavero-Redondo, Ivan ;
Alvarez-Bueno, Celia ;
Eumann Mesas, Arthur ;
Pozuelo-Carrascosa, Diana ;
Martinez-Vizcaino, Vicente .
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2020, 7 (09) :1738-1752
[24]   Pharmacological management of dilated cardiomyopathy in Duchenne muscular dystrophy: A systematic review [J].
Haddad, Christien Noel ;
Ali, Shirin ;
Stephanou, Demetra ;
Assakura, Maria Stordahl ;
Sahagian, Lilit ;
Trogkanis, Efstratios .
HELLENIC JOURNAL OF CARDIOLOGY, 2023, 74 :58-64
[25]   Clinical utility of serum biomarkers in Duchenne muscular dystrophy [J].
Hathout, Yetrib ;
Seol, Haeri ;
Han, Meng Hsuan J. ;
Zhang, Aiping ;
Brown, Kristy J. ;
Hoffman, Eric P. .
CLINICAL PROTEOMICS, 2016, 13
[26]   Clinical utility of serum biomarkers in Duchenne muscular dystrophy [J].
Yetrib Hathout ;
Haeri Seol ;
Meng Hsuan J. Han ;
Aiping Zhang ;
Kristy J. Brown ;
Eric P. Hoffman .
Clinical Proteomics, 2016, 13
[27]   Natural history of bone health in Duchenne muscular dystrophy: A systematic review and implications for the design of a clinical trial [J].
De Ford, C. ;
Guridi, M. ;
Chen, Y. ;
Murphy, A. ;
Wood, C. ;
McMillan, H. ;
Mercuri, E. ;
Crabtree, N. ;
Ward, L. .
NEUROMUSCULAR DISORDERS, 2024, 43
[28]   ESTIMATING UTILITY VALUES USING THE DUCHENNE MUSCULAR DYSTROPHY-QUALITY OF LIFE MEASURE (DMD-QOL): A NEW PREFERENCE-BASED MEASURE FOR DUCHENNE MUSCULAR DYSTROPHY [J].
Bever, A. ;
Audhya, I. Filipovic ;
Szabo, S. ;
Jayasinghe, P. ;
Feeny, D. ;
Neumann, P. ;
Malone, D. C. ;
Iannaccone, S. T. ;
Gooch, K. L. .
VALUE IN HEALTH, 2023, 26 (06) :S355-S355
[29]   CHARACTERIZATION OF PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY ACROSS PREVIOUSLY DEVELOPED HEALTH STATES [J].
Muntoni, F. ;
Goemans, N. ;
Posner, N. ;
Signorovitch, J. ;
Johnson, M. ;
Gomez-Lievano, A. ;
He, C. ;
Dorling, P. ;
Beaverson, K. ;
Alvir, J. ;
Mahn, M. ;
Ward, S. J. ;
McDonald, C. ;
Vandenborne, K. ;
Mercuri, E. .
VALUE IN HEALTH, 2023, 26 (06) :S316-S317
[30]   Characterization of patients with Duchenne muscular dystrophy across previously developed health states [J].
Muntoni, Francesco ;
Goemans, Nathalie ;
Posner, Nate ;
Signorovitch, James ;
Johnson, Michaela ;
He, Chujun ;
Dorling, Patricia ;
Beaverson, Katherine ;
Alvir, Jose ;
Mahn, Matthias ;
Ward, Susan J. ;
Mcdonald, Craig M. ;
Mercuri, Eugenio .
PLOS ONE, 2024, 19 (10)